Starpharma Holdings (ASX:SPL) EBIT per Share : A$-0.03 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings EBIT per Share?

Starpharma Holdings's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03.

During the past 5 years, the average EBIT per Share Growth Rate was -6.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was 0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Starpharma Holdings's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Starpharma Holdings was 22.20% per year. The lowest was -31.80% per year. And the median was 1.55% per year.

ASX:SPL's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Starpharma Holdings's EBIT for the six months ended in Dec. 2023 was A$-2.43 Mil.

Starpharma Holdings EBIT per Share Historical Data

The historical data trend for Starpharma Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings EBIT per Share Chart

Starpharma Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.04

-0.05

-0.06

-0.04

-0.05

Starpharma Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.02	-0.02	-0.02	-0.02	-0.01

Starpharma Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Starpharma Holdings's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.236	/	409.035
=	-0.04

Starpharma Holdings's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.431	/	410.865
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

Starpharma Holdings (ASX:SPL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Starpharma Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Starpharma Holdings (ASX:SPL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SPHRY:USA SPHRF:USA PQ6:Germany

Address

4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (ASX:SPL) Headlines

No Headlines